Results from a planned interim analysis of a randomized, double- blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis .
Intercept Pharma (ICPT) Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP,. | June 7, 2023
Efficacy, safety of oral drug for anemia treatment associated with kidney disease devdiscourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from devdiscourse.com Daily Mail and Mail on Sunday newspapers.